↓ Skip to main content

Dove Medical Press

Article Metrics

Update on optimal use of omalizumab in management of asthma

Overview of attention for article published in Journal of Asthma and Allergy, December 2010
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
53 Mendeley
Title
Update on optimal use of omalizumab in management of asthma
Published in
Journal of Asthma and Allergy, December 2010
DOI 10.2147/jaa.s14520
Pubmed ID
Authors

Girolamo Pelaia

Abstract

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Brazil 1 2%
Unknown 51 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 9 17%
Researcher 9 17%
Student > Master 8 15%
Student > Postgraduate 6 11%
Student > Ph. D. Student 4 8%
Other 10 19%
Unknown 7 13%
Readers by discipline Count As %
Medicine and Dentistry 24 45%
Agricultural and Biological Sciences 7 13%
Biochemistry, Genetics and Molecular Biology 4 8%
Chemistry 3 6%
Immunology and Microbiology 3 6%
Other 3 6%
Unknown 9 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2012.
All research outputs
#2,016,214
of 3,629,407 outputs
Outputs from Journal of Asthma and Allergy
#37
of 54 outputs
Outputs of similar age
#147,218
of 275,754 outputs
Outputs of similar age from Journal of Asthma and Allergy
#7
of 7 outputs
Altmetric has tracked 3,629,407 research outputs across all sources so far. This one is in the 25th percentile – i.e., 25% of other outputs scored the same or lower than it.
So far Altmetric has tracked 54 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,754 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.